• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型冠状病毒2（SARS-CoV-2）感染随时间推移对疫苗诱导的免疫反应的影响。

Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.

作者信息

Havervall Sebastian, Marking Ulrika, Greilert-Norin Nina, Gordon Max, Ng Henry, Christ Wanda, Phillipson Mia, Nilsson Peter, Hober Sophia, Blom Kim, Klingström Jonas, Mangsbo Sara, Åberg Mikael, Thålin Charlotte

机构信息

Department of Clinical Sciences Karolinska Institutet Danderyd Hospital Stockholm Sweden.

Department of Medical Cell Biology SciLifeLab Uppsala University Uppsala Sweden.

出版信息

Clin Transl Immunology. 2022 Apr 18;11(4):e1388. doi: 10.1002/cti2.1388. eCollection 2022.

DOI:10.1002/cti2.1388
PMID:35444806
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9015077/
Abstract

OBJECTIVE

To determine the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination.

METHODS

Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU mL) and neutralising antibody titres against ten SARS-CoV-2 variants over 7 months following BNT162b2 in SARS-CoV-2-recovered ( = 118) and SARS-CoV-2-naïve ( = 289) healthcare workers with confirmed prior SARS-CoV-2 infection. A smaller group with ( = 47) and without ( = 60) confirmed prior SARS-CoV-2 infection receiving ChAdOx1 nCoV-19 was followed for 3 months. SARS-CoV-2-specific memory T-cell responses were investigated in a subset of SARS-CoV-2-naïve and SARS-CoV-2-recovered vaccinees.

RESULTS

Vaccination with both vaccine platforms resulted in substantially enhanced T-cell responses, anti-spike IgG responses and neutralising antibodies effective against ten SARS-CoV-2 variants in SARS-CoV-2-recovered participants as compared to SARS-CoV-2-naïve participants. The enhanced immune responses sustained over 7 months following vaccination.

CONCLUSION

These findings imply that prior SARS-CoV-2 infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programmes.

摘要

目的

确定既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对新型冠状病毒肺炎（COVID-19）疫苗接种后免疫反应的长期影响。

方法

利用从社区研究中纵向收集的血液样本，我们测定了118名确诊既往感染过SARS-CoV-2的康复医护人员和289名未感染过SARS-CoV-2的医护人员在接种BNT162b2疫苗后7个月内针对10种SARS-CoV-2变体的结合抗体（世界卫生组织国际单位每毫升）和中和抗体滴度。对47名确诊既往感染过SARS-CoV-2和60名未感染过SARS-CoV-2且接种了ChAdOx1 nCoV-19疫苗的较小队列进行了3个月的随访。在一部分未感染过SARS-CoV-2和感染过SARS-CoV-2的疫苗接种者中研究了SARS-CoV-2特异性记忆T细胞反应。

结果

与未感染过SARS-CoV-2的参与者相比，两种疫苗平台接种均使感染过SARS-CoV-2的参与者的T细胞反应、抗刺突IgG反应和对10种SARS-CoV-2变体有效的中和抗体大幅增强。接种疫苗后，增强的免疫反应持续了7个月。

结论

这些发现表明，在规划加强剂量以及设计当前和未来的COVID-19疫苗计划时，应考虑既往SARS-CoV-2感染情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/7c0a1b534af3/CTI2-11-e1388-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/e573bf0022a9/CTI2-11-e1388-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/4a59b08231ae/CTI2-11-e1388-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/045f503ad729/CTI2-11-e1388-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/2fc6c7bc1ea2/CTI2-11-e1388-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/7c0a1b534af3/CTI2-11-e1388-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/e573bf0022a9/CTI2-11-e1388-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/4a59b08231ae/CTI2-11-e1388-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/045f503ad729/CTI2-11-e1388-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/2fc6c7bc1ea2/CTI2-11-e1388-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f6/9015077/7c0a1b534af3/CTI2-11-e1388-g003.jpg

相似文献

1
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.新型冠状病毒2（SARS-CoV-2）感染随时间推移对疫苗诱导的免疫反应的影响。
Clin Transl Immunology. 2022 Apr 18;11(4):e1388. doi: 10.1002/cti2.1388. eCollection 2022.
2
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.在先前感染过 SARS-CoV-2 的医护人员中，单次接种 ChAdOx1 nCoV-19 疫苗后的抗体反应。
EBioMedicine. 2021 Aug;70:103523. doi: 10.1016/j.ebiom.2021.103523. Epub 2021 Aug 12.
3
Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。
BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.
4
Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.在未感染和既往感染个体中，接受 BNT162b2 疫苗第一、第二和第三剂后，针对 SARS-CoV-2 的特异性抗体反应的差异：一项在医护人员中进行的为期 1 年的观察性研究。
Front Immunol. 2022 May 27;13:876533. doi: 10.3389/fimmu.2022.876533. eCollection 2022.
5
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
6
[Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].[既往感染过新冠病毒与未感染过新冠病毒的医护人员接种两剂新冠病毒灭活疫苗后的抗体反应：一项前瞻性观察研究]
Mikrobiyol Bul. 2022 Jan;56(1):36-48. doi: 10.5578/mb.20229904.
7
The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.接种 BNT162b2 和 mRNA-1273 后 T 细胞和 B 细胞应答的时程变化。
Clin Microbiol Infect. 2022 May;28(5):701-709. doi: 10.1016/j.cmi.2021.09.006. Epub 2021 Sep 20.
8
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.BNT162b2 新冠病毒疫苗与体液免疫应答及动力学的相关性：医护人员前瞻性、单中心、纵向队列研究。
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
9
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
10
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.

引用本文的文献

1
Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera.利用新冠病毒三聚体刺突蛋白的新型竞争性酶联免疫吸附测定法可识别混合血清中超过RBD-RBM特异性中和抗体。
Vaccines (Basel). 2024 Aug 13;12(8):914. doi: 10.3390/vaccines12080914.
2
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes.既往 COVID-19 免疫接种和/或既往感染对免疫应答和临床结局的影响。
Viruses. 2024 Apr 26;16(5):685. doi: 10.3390/v16050685.
3
Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.

本文引用的文献

1
Extended interval BNT162b2 vaccination enhances peak antibody generation.延长间隔接种BNT162b2疫苗可增强抗体峰值生成。
NPJ Vaccines. 2022 Jan 27;7(1):14. doi: 10.1038/s41541-022-00432-w.
2
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.mRNA-1273 新冠疫苗有效性临床试验的免疫相关性分析。
Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23.
3
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.BNT162b2 mRNA 疫苗标准和延长给药间隔的免疫原性。
鼻腔分泌物、唾液和血清中 SARS-CoV-2 刺突特异性 IgA 和 IgG 的比较。
Front Immunol. 2024 Mar 15;15:1346749. doi: 10.3389/fimmu.2024.1346749. eCollection 2024.
4
Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses.基于既往感染状况和加强针剂，COVID-19 疫苗加强针后的抗体纵向动力学。
Sci Rep. 2024 Feb 25;14(1):4564. doi: 10.1038/s41598-024-55245-9.
5
A Systematic Evaluation of the SARS-CoV-2 Vaccine-Induced Anti-S-RBD-Ig Response in a Population of Health Care Workers.医护人员群体中SARS-CoV-2疫苗诱导的抗S-RBD-Ig反应的系统评价
Vaccines (Basel). 2023 Sep 7;11(9):1467. doi: 10.3390/vaccines11091467.
6
Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers.医护人员中 SARS-CoV-2 的风险评估和抗体反应。
Front Public Health. 2023 Jul 21;11:1164326. doi: 10.3389/fpubh.2023.1164326. eCollection 2023.
7
SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination.自然感染和接种疫苗后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的T细胞免疫反应
Vaccines (Basel). 2023 Jun 30;11(7):1186. doi: 10.3390/vaccines11071186.
8
Varying Cellular Immune Response against SARS-CoV-2 after the Booster Vaccination: A Cohort Study from Fukushima Vaccination Community Survey, Japan.加强接种疫苗后针对新冠病毒的不同细胞免疫反应：来自日本福岛疫苗接种社区调查的队列研究
Vaccines (Basel). 2023 Apr 29;11(5):920. doi: 10.3390/vaccines11050920.
9
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy.在曾有轻度或无症状 COVID-19 的乌干达人中，阿斯利康疫苗接种的抗体反应的血清阳性率和持久性：对疫苗政策的影响。
Front Immunol. 2023 May 2;14:1183983. doi: 10.3389/fimmu.2023.1183983. eCollection 2023.
10
Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies.接受疾病修正治疗的多发性硬化症患者对SARS-CoV-2疫苗接种的短期和长期体液免疫及细胞免疫反应
Vaccines (Basel). 2023 Apr 3;11(4):786. doi: 10.3390/vaccines11040786.
Cell. 2021 Nov 11;184(23):5699-5714.e11. doi: 10.1016/j.cell.2021.10.011. Epub 2021 Oct 16.
4
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
5
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.德尔塔变异株对英国新冠病毒载量及针对新型严重急性呼吸综合征冠状病毒2感染的疫苗效力的影响。
Nat Med. 2021 Dec;27(12):2127-2135. doi: 10.1038/s41591-021-01548-7. Epub 2021 Oct 14.
6
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.循环的 SARS-CoV-2 变体对 mRNA 疫苗诱导免疫的影响。
Nature. 2021 Dec;600(7889):523-529. doi: 10.1038/s41586-021-04085-y. Epub 2021 Oct 11.
7
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.mRNA 疫苗接种后抗 SARS-CoV-2 受体结合域抗体的进化。
Nature. 2021 Dec;600(7889):517-522. doi: 10.1038/s41586-021-04060-7. Epub 2021 Oct 7.
8
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性：一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
9
An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses.评估 FluoroSpot assay 作为一种诊断工具，以确定 SARS-CoV-2 特异性 T 细胞反应。
PLoS One. 2021 Sep 30;16(9):e0258041. doi: 10.1371/journal.pone.0258041. eCollection 2021.
10
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.针对有症状和无症状 SARS-CoV-2 感染的保护相关因素。
Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29.